• Je něco špatně v tomto záznamu ?

Mitral valve prolapse: arrhythmic risk during pregnancy and postpartum

A. Sabbag, EW. Aabel, AI. Castrini, KC. Siontis, M. Laredo, J. Nizard, G. Duthoit, S. Asirvatham, O. Sehrawat, FP. Kirkels, PJ. van Rosendael, R. Beinart, MR. Acha, P. Peichl, HS. Lim, C. Sohns, R. Martins, J. Font, NNK. Truong, M. Estensen, KH. Haugaa

. 2024 ; 45 (20) : 1831-1839. [pub] 20240527

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013862

Grantová podpora
Slezak fund
288438 and #309762 Norwegian Research Council

BACKGROUND AND AIMS: Arrhythmic mitral valve prolapse (AMVP) is linked to life-threatening ventricular arrhythmias (VAs), and young women are considered at high risk. Cases of AMVP in women with malignant VA during pregnancy have emerged, but the arrhythmic risk during pregnancy is unknown. The authors aimed to describe features of women with high-risk AMVP who developed malignant VA during the perinatal period and to assess if pregnancy and the postpartum period were associated with a higher risk of malignant VA. METHODS: This retrospective international multi-centre case series included high-risk women with AMVP who experienced malignant VA and at least one pregnancy. Malignant VA included ventricular fibrillation, sustained ventricular tachycardia, or appropriate shock from an implantable cardioverter defibrillator. The authors compared the incidence of malignant VA in non-pregnant periods and perinatal period; the latter defined as occurring during pregnancy and within 6 months after delivery. RESULTS: The authors included 18 women with AMVP from 11 centres. During 7.5 (interquartile range 5.8-16.6) years of follow-up, 37 malignant VAs occurred, of which 18 were pregnancy related occurring in 13 (72%) unique patients. Pregnancy and 6 months after delivery showed increased incidence rate of malignant VA compared to the non-pregnancy period (univariate incidence rate ratio 2.66, 95% confidence interval 1.23-5.76). CONCLUSIONS: The perinatal period could impose increased risk of malignant VA in women with high-risk AMVP. The data may provide general guidance for pre-conception counselling and for nuanced shared decision-making between patients and clinicians.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013862
003      
CZ-PrNML
005      
20240905134001.0
007      
ta
008      
240725s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/eurheartj/ehae224 $2 doi
035    __
$a (PubMed)38740526
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Sabbag, Avi $u Sheba Medical Centre, Ramat-Gan, affiliated with the School of Medicine, Tel Aviv University, Tel Aviv, Israel $1 https://orcid.org/0000000342956679
245    10
$a Mitral valve prolapse: arrhythmic risk during pregnancy and postpartum / $c A. Sabbag, EW. Aabel, AI. Castrini, KC. Siontis, M. Laredo, J. Nizard, G. Duthoit, S. Asirvatham, O. Sehrawat, FP. Kirkels, PJ. van Rosendael, R. Beinart, MR. Acha, P. Peichl, HS. Lim, C. Sohns, R. Martins, J. Font, NNK. Truong, M. Estensen, KH. Haugaa
520    9_
$a BACKGROUND AND AIMS: Arrhythmic mitral valve prolapse (AMVP) is linked to life-threatening ventricular arrhythmias (VAs), and young women are considered at high risk. Cases of AMVP in women with malignant VA during pregnancy have emerged, but the arrhythmic risk during pregnancy is unknown. The authors aimed to describe features of women with high-risk AMVP who developed malignant VA during the perinatal period and to assess if pregnancy and the postpartum period were associated with a higher risk of malignant VA. METHODS: This retrospective international multi-centre case series included high-risk women with AMVP who experienced malignant VA and at least one pregnancy. Malignant VA included ventricular fibrillation, sustained ventricular tachycardia, or appropriate shock from an implantable cardioverter defibrillator. The authors compared the incidence of malignant VA in non-pregnant periods and perinatal period; the latter defined as occurring during pregnancy and within 6 months after delivery. RESULTS: The authors included 18 women with AMVP from 11 centres. During 7.5 (interquartile range 5.8-16.6) years of follow-up, 37 malignant VAs occurred, of which 18 were pregnancy related occurring in 13 (72%) unique patients. Pregnancy and 6 months after delivery showed increased incidence rate of malignant VA compared to the non-pregnancy period (univariate incidence rate ratio 2.66, 95% confidence interval 1.23-5.76). CONCLUSIONS: The perinatal period could impose increased risk of malignant VA in women with high-risk AMVP. The data may provide general guidance for pre-conception counselling and for nuanced shared decision-making between patients and clinicians.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a těhotenství $7 D011247
650    12
$a prolaps mitrální chlopně $x komplikace $x epidemiologie $7 D008945
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a dospělí $7 D000328
650    12
$a kardiovaskulární komplikace v těhotenství $x epidemiologie $7 D011249
650    _2
$a rizikové faktory $7 D012307
650    _2
$a srdeční arytmie $x epidemiologie $x etiologie $7 D001145
650    _2
$a komorová tachykardie $x epidemiologie $x etiologie $7 D017180
650    _2
$a poruchy v puerperiu $x epidemiologie $x etiologie $7 D011644
650    _2
$a defibrilátory implantabilní $7 D017147
650    _2
$a incidence $7 D015994
650    _2
$a fibrilace komor $x epidemiologie $x etiologie $7 D014693
650    _2
$a poporodní období $7 D049590
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Aabel, Eivind W $u ProCardio Center for Research Based Innovation, Department of Cardiology, Oslo University Hospital, Rikshospitalet, and University of Oslo, Sognsvannsveien 20, 0372 Oslo, Norway $1 https://orcid.org/0000000220224568
700    1_
$a Castrini, Anna Isotta $u ProCardio Center for Research Based Innovation, Department of Cardiology, Oslo University Hospital, Rikshospitalet, and University of Oslo, Sognsvannsveien 20, 0372 Oslo, Norway
700    1_
$a Siontis, Konstantinos C $u Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA
700    1_
$a Laredo, Mikael $u Sorbonne Université, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France $1 https://orcid.org/0000000273262656
700    1_
$a Nizard, Jacky $u Sorbonne Université, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
700    1_
$a Duthoit, Guillaume $u Sorbonne Université, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France $1 https://orcid.org/0000000257306946
700    1_
$a Asirvatham, Samuel $u Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA
700    1_
$a Sehrawat, Ojasay $u Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA
700    1_
$a Kirkels, Feddo P $u Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands $1 https://orcid.org/0000000213508765
700    1_
$a van Rosendael, Philippe J $u Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands
700    1_
$a Beinart, Roy $u Sheba Medical Centre, Ramat-Gan, affiliated with the School of Medicine, Tel Aviv University, Tel Aviv, Israel $1 https://orcid.org/0000000292684766
700    1_
$a Acha, Moshe Rav $u Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Jerusalem, Israel
700    1_
$a Peichl, Petr $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $1 https://orcid.org/0000000256250071 $7 xx0092197
700    1_
$a Lim, Han S $u Austin and Northern Health, University of Melbourne, Melbourne, Australia
700    1_
$a Sohns, Christian $u Clinic for Electrophysiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany $1 https://orcid.org/0000000304905862
700    1_
$a Martins, Raphael $u LTSI, Rennes University Hospital, Rennes, France
700    1_
$a Font, Jonaz $u LTSI, Rennes University Hospital, Rennes, France
700    1_
$a Truong, Nguyen N K $u Department of Interventional Cardiology, Medical University Center of Ho Chi Minh City, Ho Chi Minh, Vietnam
700    1_
$a Estensen, Mette $u ProCardio Center for Research Based Innovation, Department of Cardiology, Oslo University Hospital, Rikshospitalet, and University of Oslo, Sognsvannsveien 20, 0372 Oslo, Norway
700    1_
$a Haugaa, Kristina H $u ProCardio Center for Research Based Innovation, Department of Cardiology, Oslo University Hospital, Rikshospitalet, and University of Oslo, Sognsvannsveien 20, 0372 Oslo, Norway $u Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden $1 https://orcid.org/0000000249000453
773    0_
$w MED00009622 $t European heart journal $x 1522-9645 $g Roč. 45, č. 20 (2024), s. 1831-1839
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38740526 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133954 $b ABA008
999    __
$a ok $b bmc $g 2143586 $s 1225728
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 45 $c 20 $d 1831-1839 $e 20240527 $i 1522-9645 $m European heart journal $n Eur Heart J $x MED00009622
GRA    __
$p Slezak fund
GRA    __
$a 288438 and #309762 $p Norwegian Research Council
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace